Population
Patients with heart failure
Authors
Loading...
Potential cost barriers may limit sacubitril/valsartan use; leaves open whether affordability interventions can improve adoption.
The adoption of sacubitril/valsartan for heart failure management has been slow, potentially due to its high cost.
Sangaralingham et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: